CoChat

Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer.

Open access
Volkova, E, Willis, J A, Wells, J E, Robinson, B A, Dachs, G U, Currie, M J · 2011 · British Journal of Cancer

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: This study investigated the relationship of obesity, insulin resistance, inflammation and angiogenesis with cancer progression and survival in a colorectal cancer cohort. METHODS: Clinical and pathological data, along with anthropometric and follow-up data, were collected from 344 consecutive colorectal cancer patients. Serum samples at diagnosis were analysed by immunoassay for adiponectin, C-reactive protein (CRP), vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), insulin-like growth factor-1 (IGF-1), insulin and C-peptide. RESULTS: Serum Ang-2 and VEGF-A levels increased with tumour T stage (P=0.007 and P=0.025, respectively) and N stage (P=0.02 and P=0.03, respectively), and correlated with CRP levels (r=0.43, P<0.001 and r=0.23, P<0.001, respectively). Angiopoietin-2 correlated with C-peptide (r=0.14, P=0.007) and VEGF-A with IGF-1 in males (r=0.25, P=0.001). Kaplan-Meier analysis showed that patients with high serum levels of CRP and Ang-2 had significantly reduced survival (both P≤0.001). After adjusting for tumour stage and age, Ang-2 remained a significant predictor of survival. The CRP levels were inversely associated with survival in American Joint Committee on Cancer stage II patients (P=0.038), suggesting that CRP could be used to support treatment decisions in this subgroup. Serum markers and anthropometric measures of obesity correlated with each other, but not with survival. CONCLUSION: Our study supports the concept that obesity-related inflammation, rather than obesity itself, is associated with colorectal cancer progression and survival. The study confirms serum Ang-2 as a predictive marker for outcome of colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6606005

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Survival of colorectal cancer patients from surgery to death from any cause by Kaplan–Meier survival analysis. Survival between groups with high and low serum (A) CRP, (B) Ang-2 and (C) VEGF-A. (D) Survival of patients with AJCC stage II disease between groups with high and low serum CRP. Median values were used as cut points for high vs low values.
Figure 1 Survival of colorectal cancer patients from surgery to death from any cause by Kaplan–Meier survival analysis. Survival between groups with high and low serum (A) CRP, (B) Ang-2 and (C) VEGF-A. (D) Survival of patients with AJCC stage II disease between groups with high and low serum CRP. Median values were used as cut points for high vs low values.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ministry of Health (2007) Diabetes surveillance: population-based estimates and projections for New Zealand, 2001–2011: Public Health Intelligence Occasional Bulletin No. 46. Ministry of Health: Wellington. http://www.moh.govt.nz/moh.nsf/indexmh/diabetes-suveillance-population-estimates-projections-2001-2011, accessed 21 April 2010

Cited by

See all 78

Metadata

Authors
Volkova, E., Willis, J. A., Wells, J. E., Robinson, B. A., Dachs, G. U., & Currie, M. J.
Affiliations
  • University of Otago (NZ)
  • Christchurch Hospital (NZ)
Corresponding author
Currie, M J
Venue
British Journal of Cancer
Published
2010-11-16
Volume
104
Issue
1
Pages
51-59
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1987497125
Cited by
78
References
55
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 1 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 6 · 2014: 7 · 2013: 8 · 2012: 6
FWCI
2.85
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Tertiary Education Commission
  • University of Otago
  • Cancer Society of New Zealand
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
colorectal cancer, angiopoietin-2, C-reactive protein, obesity, insulin resistance, inflammation, angiogenesis, VEGF-A, insulin-like growth factor I, adiponectin, cancer survival, prognostic factors, tumor stage, obesity-associated inflammation
MeSH terms
Adenocarcinoma, Adult, Aged, Aged, 80 and over, C-Peptide, C-Reactive Protein, Enzyme-Linked Immunosorbent Assay, Female, Humans, Insulin, Insulin Resistance, Insulin-Like Growth Factor I, Male, Middle Aged, Obesity, Prospective Studies, Colorectal Neoplasms, Biomarkers, Body Mass Index, Survival Rate, Treatment Outcome, Vascular Endothelial Growth Factor A, Angiopoietin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.